equine conjugated estrogens / Generic mfg. - LARVOL DELTA

Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. (PubMed, PLoS Med) - P4 | "In these KEEPS Continuation analyses, there were no long-term cognitive effects of short-term exposure to mHT started in early menopause versus placebo. These data provide reassurance about the long-term neurocognitive safety of mHT for symptom management in healthy, recently postmenopausal women, while also suggesting that mHT does not improve or preserve cognitive function in this population."

Clinical • Journal • Observational data

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Mackay Memorial Hospital | N=200 ➔ 300

Enrollment change • Overactive Bladder

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Mackay Memorial Hospital

New P4 trial • Overactive Bladder

Drugs for menopausal symptoms. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration. (PubMed, Hum Genet) - "Cisplatin-induced acute kidney injury (CP-AKI) is a common complication in cancer patients. Drug prediction and molecular docking were further used to propose that drugs targeting TACSTD2 may have therapeutic potential in CP-AKI, such as parthenolide, progesterone, premarin, estradiol and rosiglitazone. Our findings suggest a significant association between ferroptosis and the development of CP-AKI, with TACSTD2 playing a crucial role in modulating ferroptosis, which provides novel perspectives on the pathogenesis and treatment of CP-AKI."

Journal • Acute Kidney Injury • Nephrology • Oncology • Renal Disease • HMGB1 • IRF6 • TACSTD2

Establishing a Rationale for Compounding Hormone Replacement Therapy. (PubMed, Int J Pharm Compd) - "Premarin is no longer at the top of the heap, and there are topical, commercial products that contain bioidentical estradiol, and capsules that contain the same progesterone that we use. Our compounding advantage comes from our abilities to prepare unique patient-specific products, and, very importantly, from our growing understanding of hormone receptors; we now know there are two main estrogen receptors, 1) estrogen receptor alpha and 2) estrogen receptor beta, and the growing knowledge base associated with the discovery of estrogen receptor beta is quite significant."

Journal • ER

Physical energies for the management of genitourinary syndrome of menopause: An overview of a systematic review and network meta-analysis. (PubMed, Int J Gynaecol Obstet) - "Several gaps in the use of physical energy for managing GSM still need to be addressed. The small number of blind clinical trials made the results fragile."

Journal • Retrospective data • Review • Sexual Disorders • Women's Health

Effects of estrogen and raloxifene on synaptic density in the hippocampal CA1 region of ovariectomized rats. (PubMed, Clinics (Sao Paulo)) - "The present data suggest that the raloxifene effect may be lower than that of estrogen, even early or late treatment, on synaptic density in the hippocampus."

Journal • Preclinical • Anesthesia

Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial. (PubMed, Menopause) - "There was no evidence of cardiovascular and/or metabolic benefits or adverse effects associated with 4 years use of oral or transdermal forms of hormone therapy by recently menopausal women with good cardiovascular health after 10 years."

Journal • Cardiovascular • Diabetes • Metabolic Disorders

PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Nephrology • Reperfusion Injury • Transplantation

Association Between the Route of Administration and Formulation of Estrogen Therapy and Hypertension Risk in Postmenopausal Women: A Prospective Population-Based Study. (PubMed, Hypertension) - "Oral estrogen-only HT use was associated with an increased risk of hypertension in women. In women using estrogen-only HT, nonoral estradiol at the lowest dose and for the shortest time-period is associated with the lowest risk of hypertension."

Journal • Cardiovascular • Hypertension

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Mayo Clinic | Recruiting ➔ Completed | N=94 ➔ 12

Enrollment change • Trial completion • Infectious Disease • Nephrology

Effect of Magnetic Nanoparticles on Hormone Level Changes During Perimenopausal Period and Regulation of Bone Metabolism. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "Rats in the estrogen treatment group were given Premarin suspension by gavage...Compared with the young control group, the humeral dry weight, wet weight, bone density, and bone mineral content, serum E2, OT, and BGP content in the perimenopausal period model group were reduced, while the serum BALP, CTX-I, and TRACP -5b content was increased (P<0.05). It was verified that nerve magnetic stimulation based on PTMP-MAA@ Fe3O4 NP increased the serum estrogen level of female rats during the perimenopausal period, increased the bone density of rats, promoted bone formation, and regulated bone metabolism."

Journal • Osteoporosis • Rheumatology • TRAP

[VIRTUAL] Improvement in OAB Symptoms After Vaginal Estrogen Therapy Is Associated with Measurable Pelvic Microbiome Changes (AUA 2020) - P=N/A, P4 | "Introduction: Improvement in OAB Symptoms After Vaginal Estrogen Therapy Is Associated with Measurable Pelvic Microbiome Changes Analysis of data from post-menopausal participants in two trials (NCT02524769 and NCT02835846) who chose vaginal estrogen as their primary OAB treatment and used 0.5 grams of Premarin Cream® twice weekly for 12 weeks. The mechanism of OAB symptom relief following vaginal estrogen use may relate to decreased microbial diversity. Following treatment, microbiota characteristics are more similar to a pre-menopausal state. Source of Funding: This study was funded by Loyola Urogynecology Division Research Fund, an Investigator Initiated grant from the Kimberly Clark Corporation, two NIH awards to Drs."

Late-breaking abstract • Gynecology

DEVELOPMENT OF SCAD IN THE SETTING OF HORMONE THERAPY FOR GENDER AFFIRMING THERAPY IN A TRANSGENDERED WOMAN (ACC-WCC 2023) - "We present a case of SCAD occurring in a transgendered woman undergoing hormone replacement therapy.Case: A 58-year-old transgendered woman on oral conjugated estrogens (Premarin) hormone replacement therapy with no prior cardiac history presented to the emergency department after developing dyspnea on exertion and left sided substernal chest pain following a vigorous bike ride...Chest pain resolved with medical therapy, and she was discharged on beta blocker and dual antiplatelet therapy.Decision-making: Preferred management for patients with SCAD has conventionally been conservative therapy with long-term aspirin and beta blocker, short-term clopidogrel, and avoidance of any inciting medications and/or lifestyle factors. Considering the increase in exogenous gender affirming hormone treatment in the transgender population, further data and recommendations are required to guide the optimal dosing and regimens for hormone therapy in this population. Counseling regarding..."

Clinical • Cardiovascular • Coronary Artery Disease • Pain • Pulmonary Disease

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection (clinicaltrials.gov) - P=N/A | N=94 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2023 ➔ Apr 2023 | Trial primary completion date: Dec 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Infectious Disease • Nephrology

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury. (PubMed, Neurosci Biobehav Rev) - "Several estrogens were examined by the included studies: estrogen, estradiol benzoate, Premarin, isopsoralen, genistein, and selective estrogen receptor modulators...A STRING functional network analysis of proteins modulated by estrogen after SCI demonstrated that estrogen simultaneously upregulates known neuroprotective pathways, such as HIF-1, and downregulates pro-inflammatory pathways, including IL-17. These findings highlight the strong therapeutic potential of estrogen and estrogenic compounds after SCI."

Journal • Review • CNS Disorders • Orthopedics • HIF1A • IL17A

The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. (PubMed, Menopause) - "Thirty commentaries challenging WHI findings were identified. All were reviewed, and issues needing response were identified. Findings from the meta-analysis from the Collaborative Group on Hormonal Factors in Breast Cancer and the Million Women Study were summarized and compared with finding in the two WHI randomized trials evaluating estrogen therapy and estrogen plus progestin. Based on the randomized clinical trials, estrogen therapy, for women with prior hysterectomy, decreases breast cancer incidence and mortality. In contrast, estrogen plus progestin increases breast cancer incidence, which persists through two decades. Women considering estrogen plus progestin use for vasomotor symptoms should understand the breast cancer risk."

Clinical • Journal • Breast Cancer • Gynecology • Oncology • Solid Tumor • Women's Health

Pharmacokinetic Study of Conjugated Equine Estrogens in Healthy Chinese Postmenopausal Women Using a Parallel Two-Column LC-MS/MS Method. (PubMed, Clin Pharmacokinet) - "The fully validated assay was successfully applied to a pharmacokinetic study in healthy postmenopausal Chinese women after oral administration of a conjugated equine estrogen tablet. This study suggests that Chinese postmenopausal women achieve the same level of unconjugated estrogens in plasma at a lower dose of conjugated equine estrogens than North American women."

Journal • PK/PD data

PERT: Intravenous Estrogen in Kidney Transplant Study (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: University of Pennsylvania | Trial completion date: Jan 2022 ➔ Jan 2025 | Trial primary completion date: Jan 2022 ➔ Jan 2025

Trial completion date • Trial primary completion date • Cardiovascular • Nephrology • Reperfusion Injury • Transplantation

"Never stop asking questions - #Premarin #estrogen #Horses .@pfizer are you still using pregnant horse urine for your estrogen meds?" (@greennomad61)

Premarin Reduces Neurodegeneration and Promotes Improvement of Function in an Animal Model of Spinal Cord Injury. (PubMed, Int J Mol Sci) - "The attenuation of glial activation with decreased inflammation and cell death, and increased angiogenesis by PRM led to improved functional outcome as determined by the BBB locomotor scale. These results suggest that PRM treatment has significant therapeutic implications for the improvement of post-SCI outcome."

Journal • Preclinical • CNS Disorders • Immunology • Inflammation • Orthopedics

"I assume so, judging from the rarity of Premarin prescriptions." (@DavidJuurlink)

Osteoprotective Effects in Postmenopausal Osteoporosis Rat Model: Oral Tocotrienol vs. Intraosseous Injection of Tocotrienol-Poly Lactic-Co-Glycolic Acid Combination. (PubMed, Front Pharmacol) - "The estrogen group (OVX + ESTO) and tocotrienol group (OVX + TTO) were given daily oral gavages of Premarin (64.5 mg/kg) and annatto-tocotrienol (60 mg/kg), respectively...Both groups also showed improvement in bone strength by the significantly higher stress, strain, stiffness, and Young's modulus parameters. In conclusion, daily oral tocotrienol and one-time intraosseous injection of tocotrienol-PLGA combination were equally effective in offering protection against ovariectomy-induced bone changes."

Journal • Preclinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis (clinicaltrials.gov) - P1; N=100; Not yet recruiting; Sponsor: Fayoum University

Clinical • New P1 trial • Gynecology • Vaginal Atrophy • Vaginitis